We are live on
!
Find out more
EWM
Essex Woodlands Management Portfolio holdings
AUM
$254M
1-Year Est. Return
4.59%
This Fund
S&P 500
This Quarter
Est. Return
+21.78%
1 Year Est. Return
+4.59%
3 Year Est. Return
+54.96%
5 Year Est. Return
+25.37%
10 Year Est. Return
+254.56%
AUM
$553M
AUM Growth
-$10.4M
(-1.8%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-18.92%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
3
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$56M |
| 2 |
Axogen
AXGN
|
+$27.1M |
| 3 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$21.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.69% |
Similar funds
1W
TSM
LI
LIA
IGM
WWM
MWM
LRIC
Essex Woodlands Management's Q4 2017 Portfolio in Review
As of Q4 2017, Essex Woodlands Management held 9 positions worth $553M, down 1.8% from $564M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Essex Woodlands Management withdrew a net $105M in Q4 2017, reducing 3 holdings. Its largest reduction was Abiomed Inc, cutting an estimated $56M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.
- Essex Woodlands Management's biggest Q4 2017 reduction was Abiomed Inc, cutting an estimated $56M.
- Essex Woodlands Management's ten largest holdings make up 100% of its $553M portfolio in Q4 2017.
- Essex Woodlands Management opened 0 new positions and closed 0 in Q4 2017.
- Essex Woodlands Management's portfolio value fell 1.8% quarter-over-quarter to $553M.
Based on Essex Woodlands Management's 13F filing for Q4 2017, filed 13 Feb 2018.